Dose administration aids: Pharmacists' role in improving patient care

Australasian Medical Journal

Volumn 4, Issue 4, 2011, Pages 183-189

  Haywood, A ^a   Llewelyn, V ^b   Robertson, S ^b   Mylrea, M ^b   Glass, B ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Compliance (dose administration) aid; Patient care; Quality; Repackaging; Safety; Storage

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; ATENOLOL; CLOZAPINE; FUROSEMIDE; HOSPIRA; PARACETAMOL; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE HEART INFARCTION; AUSTRALIA; COGNITIVE DEFECT; COLOR; COMMUNITY; CONTROLLED STUDY; DISSOLUTION; DRUG HYDROLYSIS; DRUG MANUFACTURE; DRUG PACKAGING; DRUG STABILITY; DRUG USE; GOVERNMENT; HARDNESS; HEALTH CARE; HEALTH CARE ACCESS; HEALTH PROGRAM; HEALTH SERVICE; HEART FAILURE; HUMAN; HYPERTENSION; INFORMATION; INFORMED CONSENT; LOW DRUG DOSE; MEDICAL PRACTICE; PATIENT CARE; PHARMACIST; PHOTOSENSITIVITY; REVIEW; SCHIZOPHRENIA; STROKE;

EID: 79955656966     PISSN: None     EISSN: 18361935     Source Type: Journal    
DOI: 10.4066/AMJ.2011.693     Document Type: Review

References (30)

1. Church C, Smith J. How stable are medicines moved from original packs into compliance aids? Pharm J 2006; 276: 75-81.
2. Nunney JM, Rayner DKT. How are multicompartment compliance aids used in primary care? Pharm J 2001; 267: 784-9.
3. Walker R. Stability of medicinal products in compliance devices. Pharm J 1992; 25: 124-6.
4. Ware GJ, Holford NH, Davison JG, Harris RG. Unit-ofissue medicine administration: time and cost-benefits in a geriatric unit. Aust J Hosp Pharm 1994; 24: 329-32.
5. Australian Government Department of Health and Aging. Pharmacy: Dose Administration Aids Program-Fact Sheet. Accessed 19 January 2011. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/ppsac-qa-daa.
6. Llewelyn VK, Mangan MF, Glass BD. Stability of sodium valproate tablets repackaged into dose administration aids. J Pharm Pharmacol 2010; 62: 838-43.
7. Chan K, Swinden J, Donyai P. Pilot study of the shortterm physico-chemical stability of atenolol tablets stored in a multi-compartment compliance aid. EJHP Sci 2007; 13: 60-6.
8. Pharmacy Guild of Australia. Professional Pharmacy Services: Dose Administration Aids. Accessed 19 January 2011. Availble from: http://www.guild.org.au/pps/content.asp?id=1425.
9. Aulton ME. Aulton's Pharmaceutics. The Design and Manufacture of Medicines. 3rd Ed. Edinburgh: Churchill Livingstone; 2007.
10. US Pharmacopeial Convention Inc. US Pharmacopeia 33-National formulary 28 <1191> Stability considerations in dispensing practice. 2010.
11. Simmons D, Upjohn M, Gamble GD. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care 2000; 23: 153-6.
12. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006 6; 296: 2563-71.
13. Professional Practice Standards. Version 4. Standard 7: Dose Administration Aids Service: Pharmaceutical Society of Australia; 2010.
14. Pharmaceutical Society of Australia. Guidelines and standards for pharmacists: Dose administration aids service. July 2007. Accessed 19 January 2011. Available from: http://www.psa.org.au/site.php?id=2065.
15. Glass BD, Haywood A, Llewelyn V, Mangan M. Compliance aids and medicine stability: new evidence of quality assurance. Curr Drug Saf 2009; 4: 74-8.
16. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A(R2): ICH Steering Committee, Feb 2003.
17. Pharmaceutical Society of Australia. Guidelines and standards for pharmacists. Dose Administration Aids Service. Accessed 18 November 2010. Available from: http://www.psa.org.au/site.php?id=2065.
18. Royal Pharmaceutical Society of Great Britain. Medicines, Ethics, and Practice: A Guide for Pharmacists, Volume 27. London: Pharmaceutical Press, 2003.
19. US Pharmacopeial Convention Inc. US Pharmacopeia 33-National formulary 28 <681> Repackaging into single-unit containers and unit-dose containers for nonsterile solid and liquid dosage forms. 2010.
20. Mangan M, Haywood A, Glass BD. Aspirin Repackaged: Caution in Practice. Proceedings of the Australasian Pharmaceutical Science Association Annual Conference. 2009.
21. Perks S, Robertson S, Haywood A, Glass BD. Stability of Clozapine Repackaged into Dose Administration Aids. Proceedings of the Australasian Pharmaceutical Science Association Annual Conference. 2010.
22. Bowen L, Mangan M, Haywood A, Glass BD. Stability of frusemide tablets repackaged in Dose Administration Aids. J Pharm Prac Res 2007; 37: 178-81.
23. Haywood A, Mangan M, Glass BD. Stability implications of repackaging paracetamol tablets into Dose Administration Aids. J Pharm Prac Res 2006; 36: 21-4.
24. Glass B, Mangan M, Haywood A. Prochlorperazine tablets repackaged into dose administration aids: can the patient be assured of quality? J Clin Pharm Ther 2009; 34: 161-9.
25. ICH Harmonised Tripartite Guideline. Stability Testing: Photostability testing of new drug substances and products Q1B: ICH Steering Committee, Nov 1996.
26. Moore DE, Tamat SR. Photosensitization by drugs: photolysis of some chlorine-containing drugs. J Pharm Pharmacol 1980; 32: 172-7.
27. Nejmeh M, Pilpel N. The effect of the photodecomposition of chlorpromazine on lecithin monolayers. J Pharm Pharmacol 1978; 30: 748-53.
28. Kohara T, Koyama T, Fujimura M, Tanaka H, Maeda J, Fujimoto T, et al. Y-931, a novel atypical antipsychotic drug, is less sensitive to oxidative phenomena. Chem Pharm Bull (Tokyo) 2002; 50: 818-21.
29. Annemans L, Wittrup-Jensen K, Bueno H. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention. J Med Econ 2010; 13: 418-27.
30. Marriott JL, Nation RL. Splitting tablets. Aust Prescr 2002; 25: 133-5.